Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Real-World” ICD Benefit Displayed In Boston Sci Latitude Network Data

This article was originally published in The Gray Sheet

Executive Summary

New "real-world" data affirming the long-term benefits of implantable cardioverter defibrillators for heart failure patients highlighted the late-breaking trial sessions of the Heart Rhythm Society's 2009 conference in Boston last week

You may also be interested in...



Only 8 Percent Of Older ICD-Eligible Heart Failure Patients Get An ICD, Study Finds

Improved patient follow up and communications may be needed to get implantable defibrillators to more patients who need them, researchers say following a recent study finding fewer than 10 percent of eligible patients with low ejection fraction received an ICD within a year after a heart attack, even though ICD implants were associated with lower risk-adjusted two-year mortality in this group.

Research In Brief

"Real-world" ICD data

Research In Brief

"Real-world" ICD data

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027456

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel